Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 169

1.

Prognostic significance of C-reactive protein polymorphism and KRAS/BRAF in synchronous liver metastasis from colorectal cancer.

Huang CJ, Teng HW, Chien CC, Lin JK, Yang SH.

PLoS One. 2013 Jun 3;8(6):e65117. doi: 10.1371/journal.pone.0065117. Print 2014.

2.

BRAF mutation is a prognostic biomarker for colorectal liver metastasectomy.

Teng HW, Huang YC, Lin JK, Chen WS, Lin TC, Jiang JK, Yen CC, Li AF, Wang HW, Chang SC, Lan YT, Lin CC, Wang HS, Yang SH.

J Surg Oncol. 2012 Aug 1;106(2):123-9. doi: 10.1002/jso.23063. Epub 2012 Feb 13.

PMID:
22331825
3.

Incidence and prognostic impact of KRAS and BRAF mutation in patients undergoing liver surgery for colorectal metastases.

Karagkounis G, Torbenson MS, Daniel HD, Azad NS, Diaz LA Jr, Donehower RC, Hirose K, Ahuja N, Pawlik TM, Choti MA.

Cancer. 2013 Dec 1;119(23):4137-44. doi: 10.1002/cncr.28347. Epub 2013 Sep 19.

4.

Poor prognosis of KRAS or BRAF mutant colorectal liver metastasis without microsatellite instability.

Umeda Y, Nagasaka T, Mori Y, Sadamori H, Sun DS, Shinoura S, Yoshida R, Satoh D, Nobuoka D, Utsumi M, Yoshida K, Yagi T, Fujiwara T.

J Hepatobiliary Pancreat Sci. 2013 Feb;20(2):223-33. doi: 10.1007/s00534-012-0531-9.

PMID:
23010994
5.

RAC1b overexpression correlates with poor prognosis in KRAS/BRAF WT metastatic colorectal cancer patients treated with first-line FOLFOX/XELOX chemotherapy.

Alonso-Espinaco V, Cuatrecasas M, Alonso V, Escudero P, Marmol M, Horndler C, Ortego J, Gallego R, Codony-Servat J, Garcia-Albeniz X, Jares P, Castells A, Lozano JJ, Rosell R, Maurel J.

Eur J Cancer. 2014 Jul;50(11):1973-81. doi: 10.1016/j.ejca.2014.04.019. Epub 2014 May 12.

PMID:
24833563
6.

Comparison of neuroendocrine differentiation and KRAS/NRAS/BRAF/PIK3CA/TP53 mutation status in primary and metastatic colorectal cancer.

Kleist B, Kempa M, Novy M, Oberkanins C, Xu L, Li G, Loland C, Poetsch M.

Int J Clin Exp Pathol. 2014 Aug 15;7(9):5927-39. eCollection 2014.

7.

EGFR, BRAF and KRAS status in patients undergoing pulmonary metastasectomy from primary colorectal carcinoma: a prospective follow-up study.

Schweiger T, Hegedüs B, Nikolowsky C, Hegedüs Z, Szirtes I, Mair R, Birner P, Döme B, Lang G, Klepetko W, Ankersmit HJ, Hoetzenecker K.

Ann Surg Oncol. 2014 Mar;21(3):946-54. doi: 10.1245/s10434-013-3386-7. Epub 2013 Nov 27.

PMID:
24281417
8.

Prognostic value of KRAS and BRAF mutations in curatively resected colorectal cancer.

Kadowaki S, Kakuta M, Takahashi S, Takahashi A, Arai Y, Nishimura Y, Yatsuoka T, Ooki A, Yamaguchi K, Matsuo K, Muro K, Akagi K.

World J Gastroenterol. 2015 Jan 28;21(4):1275-83. doi: 10.3748/wjg.v21.i4.1275.

9.

Influence of KRAS mutation status in metachronous and synchronous metastatic colorectal adenocarcinoma.

Rose JS, Serna DS, Martin LK, Li X, Weatherby LM, Abdel-Misih S, Zhao W, Bekaii-Saab T.

Cancer. 2012 Dec 15;118(24):6243-52. doi: 10.1002/cncr.27666. Epub 2012 Jun 6.

10.

The prognostic values of EGFR expression and KRAS mutation in patients with synchronous or metachronous metastatic colorectal cancer.

Huang CW, Tsai HL, Chen YT, Huang CM, Ma CJ, Lu CY, Kuo CH, Wu DC, Chai CY, Wang JY.

BMC Cancer. 2013 Dec 13;13:599. doi: 10.1186/1471-2407-13-599.

11.

A let-7 microRNA SNP in the KRAS 3'UTR is prognostic in early-stage colorectal cancer.

Smits KM, Paranjape T, Nallur S, Wouters KA, Weijenberg MP, Schouten LJ, van den Brandt PA, Bosman FT, Weidhaas JB, van Engeland M.

Clin Cancer Res. 2011 Dec 15;17(24):7723-31. doi: 10.1158/1078-0432.CCR-11-0990. Epub 2011 Oct 12.

12.

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.

Di Nicolantonio F, Martini M, Molinari F, Sartore-Bianchi A, Arena S, Saletti P, De Dosso S, Mazzucchelli L, Frattini M, Siena S, Bardelli A.

J Clin Oncol. 2008 Dec 10;26(35):5705-12. doi: 10.1200/JCO.2008.18.0786. Epub 2008 Nov 10.

13.

High MACC1 expression in combination with mutated KRAS G13 indicates poor survival of colorectal cancer patients.

Ilm K, Kemmner W, Osterland M, Burock S, Koch G, Herrmann P, Schlag PM, Stein U.

Mol Cancer. 2015 Feb 14;14:38. doi: 10.1186/s12943-015-0316-2.

14.
15.

The BRAF mutation is associated with the prognosis in colorectal cancer.

Ahn TS, Jeong D, Son MW, Jung H, Park S, Kim H, Bae SB, Kim HJ, Jeon YW, Lee MS, Baek MJ.

J Cancer Res Clin Oncol. 2014 Nov;140(11):1863-71. doi: 10.1007/s00432-014-1735-y. Epub 2014 Jun 19.

PMID:
24942334
16.

Prognostic relevance of KRAS and BRAF mutations in Japanese patients with colorectal cancer.

Nakanishi R, Harada J, Tuul M, Zhao Y, Ando K, Saeki H, Oki E, Ohga T, Kitao H, Kakeji Y, Maehara Y.

Int J Clin Oncol. 2013 Dec;18(6):1042-8. doi: 10.1007/s10147-012-0501-x. Epub 2012 Nov 29.

PMID:
23188063
17.

Somatic gene mutations in African Americans may predict worse outcomes in colorectal cancer.

Kang M, Shen XJ, Kim S, Araujo-Perez F, Galanko JA, Martin CF, Sandler RS, Keku TO.

Cancer Biomark. 2013;13(5):359-66. doi: 10.3233/CBM-130366.

18.

Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer.

Souglakos J, Philips J, Wang R, Marwah S, Silver M, Tzardi M, Silver J, Ogino S, Hooshmand S, Kwak E, Freed E, Meyerhardt JA, Saridaki Z, Georgoulias V, Finkelstein D, Fuchs CS, Kulke MH, Shivdasani RA.

Br J Cancer. 2009 Aug 4;101(3):465-72. doi: 10.1038/sj.bjc.6605164. Epub 2009 Jul 14.

19.

Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes.

Pentheroudakis G, Kotoula V, De Roock W, Kouvatseas G, Papakostas P, Makatsoris T, Papamichael D, Xanthakis I, Sgouros J, Televantou D, Kafiri G, Tsamandas AC, Razis E, Galani E, Bafaloukos D, Efstratiou I, Bompolaki I, Pectasides D, Pavlidis N, Tejpar S, Fountzilas G.

BMC Cancer. 2013 Feb 2;13:49. doi: 10.1186/1471-2407-13-49.

20.

Clinicopathological characteristics and prognostic impact of colorectal cancers with NRAS mutations.

Ogura T, Kakuta M, Yatsuoka T, Nishimura Y, Sakamoto H, Yamaguchi K, Tanabe M, Tanaka Y, Akagi K.

Oncol Rep. 2014 Jul;32(1):50-6. doi: 10.3892/or.2014.3165. Epub 2014 May 6.

PMID:
24806883
Items per page

Supplemental Content

Write to the Help Desk